Skip to content
DataLookout
Menu

NCT02577120

Wound Healing Endpoint and Recurrence

StatusCompleted
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 14 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 11 words Show 7 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Feb 2029 to May 31, 2023
    • Enrollment target: estimated 100 to confirmed 106
    • Study completion date changed from estimate of Feb 2034 to Dec 16, 2025
    • Study description revised
    • Site details revised at 3 of 3 sites
    • Publications: details revised at 20 of 21 entries
  2. Notable Trial status: Suspended to Active, Not Recruiting
    • Collaborators shortened, about 6 words
    v14
  3. Notable Phase: Phase 4 to Phase 1/2v13 Show 10 more changesShow less
    • Lead sponsor: Indiana University to Sashwati Roy
    • Enrollment target: 265 to 100
    • Primary completion date: Feb 2025 to Feb 2029
    • Eligibility criteria expanded, about 13 words
    • Primary endpoints: 2 to 1
    • Study sites: 1 to 3
    • Study completion date: Feb 2025 to Feb 2034
    • Interventions: Ceramiseal (Biological), Epiceram Skin Barrier Function (Device), Vaseline Petroleum Jelly (Biological) to Epiceram Skin Barrier Function (Device), Vaseline Petroleum Jelly (Biological)
    • Study description shortened, about 577 words
    • Study arms: 5 to 2
  4. Stopped Trial status: Recruiting to Suspended Sponsor's reason: The study is temporarily suspended as the PI works to transfer the study to her new institution.
    • Primary and study completion dates: Dec 2023 to Feb 2025
    • Start date: Jan 9, 2019 to Jan 8, 2019
    • Site details revised
    v12
  5. Notable Phase: Not specified to Phase 4
    • Site contact updated
    v11
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Site contact updatedv9
  2. Notable Primary and study completion dates: Dec 2020 to Dec 2023
    • Start date: Jan 15, 2019 to Jan 9, 2019
    v8
  3. Notable Eligibility criteria expanded, about 16 words
    • Study description expanded, about 14 words
    • Site contact updated
    v7
  4. Minor Start date changed from estimate of Jan 30, 2019 to Jan 15, 2019v6
  5. Notable Lead sponsor: Ohio State University to Indiana University
    • Primary and study completion dates: Dec 2018 to Dec 2020
    • Start date: May 2015 to Jan 30, 2019
    • Study sites: 2 to 1
    v5
  6. Minor Site contacts updated at 2 of 2 sitesv4
  7. Minor Site details revised at 2 of 2 sitesv3
  8. Notable Eligibility criteria expanded, about 42 words
    • Study description expanded, about 21 words
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

TEWL
Timeframe: 12 weeks

Arms and interventions

TEWL - EpiceramExperimental

Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects

TEWL - Vaseline Petroleum JellyPlacebo comparator

Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects

Devices: Epiceram Skin Barrier Function

Biologicals: Vaseline Petroleum Jelly

Sites

3 sites in 1 country